Longer-term Data for Kites Yescarta in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
94% of Patients Achieved a Response at 18 Months in Pivotal ZUMA-5 Trial Yescarta Reduced Risk of Death by 58% Compared to Current Therapies in Weighted Analysis of ZUMA-5 Compared to SCHOLAR-5 External Control Cohort Late-breaking Data Presented at European Hematology Association 2021 Kite, a Gilead Company today announced follow-up results from the pivotal ZUMA-5 trial of Yescarta ® the first and .
(BPT) - Peanut allergy is the most common food allergy in children in the U.S. and affects approximately 1.3 million children between the ages of 4 through 17.1
Study met primary and key secondary endpoints, demonstrating a highly statistically significant improvement in event-free survival, complete response rate and progression-free survival compared to standard of care Breyanzi safety results consistent with data from pivotal TRANSCEND NHL 001 trial Results represent the first time a therapy has demonstrated benefit compared to high-dose chemotherapy and stem cell .
71% of Adult Patients in Phase 2 ZUMA-3 Study Achieved a Complete Response Following a Single Infusion of Tecartus - If Approved, Tecartus Would Be the First and Only CAR T-Cell Therapy Approved for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia Kite, a Gilead Company announced today results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, .